Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Hot Flashes 2Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 1Prostatic Neoplasms 1Head and Neck Neoplasms 1Depression 1Breast Neoplasms 1

Interventions

Psilocybin 6Therapeutics 2Ketamine 2Exercise 2Venlafaxine Hydrochloride 1Vegetables 1Terminal Care 1Self-Management 1SLI381 1Psychotherapy 1Psychosocial Intervention 1Psychiatric Rehabilitation 1Professional Autonomy 1Niacin 1Mirtazapine 1Minocycline 1Methylphenidate 1Mental Status and Dementia Tests 1Melatonin 1Medical Marijuana 1Interpersonal Psychotherapy 1Injections 1Infliximab 1Gemcitabine 1Fruit 1Fluoxetine 1Ethanol 1Doxorubicin 1Donepezil 1Dignity Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Depression × Venlafaxine Hydrochloride × Clear all
NCT05724849 2024-01-18

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

Phase 2 Withdrawn
Head & Neck

Depression, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡